Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer

Inclusion Criteria:

* Age \>18
* WHO performance status 0-2
* Life expectancy ≥ 3 months
* Patients receiving androgen-suppressive therapy in the form of chirurgical castration by orchiectomy or pulpectomy,or medical by LHRH agonist or antagonist with or without anti-androgen or all treatment blocking non gonadic testosterone fraction
* Resulting to testosteronemia \<0,5 ng/ml
* Histologically confirmed adenocarcinomia of prostate cancer and documented hormone independant metastatic disease - defined by: objective progression with at least one measurable lesion and/or evaluable lesion according to RECIST criteria and /or a rise in PSA level ("rising PSA")
* Total bilirubin ≤ upper limit of normal (ULN).
* AST and ALT ≤ 1.5 times ULN. Alkaline phosphatase ≤ 2.5 times ULN.
* Serum creatinine \< 140 µmol/L or creatinine clearance \> 60 mL/ min.
* Neutrophil count \> 2.109 L-1.
* Platelet count ≥ 100,000/mm3.
* Hemoglobin ≥ 10 g/dL
* Not previous chemotherapy, except Estracyt
* No liver, kidney or heart failure link to treatment
* No malabsorption syndrome or disease significantly affecting gastrointestinal function
* Prior radiotherapies are permetted withing four weeks of the first study treatment and must be \< 25 % of the bone marrow, and all adverse events must be resolved
* Prior surgery are permitted.

Exclusion Criteria:

* Age \< 18
* History of psychiatric disorders including psychotic disorder, dementia or seizures that would prohibit the understanding, observance and giving of informed consent
* Previous or concomitant other malignancies except basal or squamous cell carcinoma of the skin or other cancer curatively treated with surgery and/or radiotherapy
* Patients should not have symptomatic brain metastasis
* Concurrent severe and/or uncontrolled co-morbid medical condition
* Malabsorption syndrome or disease significantly affecting gastro-intestinal function or major resection of the stomach, proximal small bowel or grade \> 2 dysphagia
* Patients with uncontrolled infection
* History of significant neurologic (i.e. peripheral neuropathy grade \> 2 using NCI-CTC criteria v3.0)
* Patients should not have received NSAIDs or COX2 inhibitors within the three weeks prior to starting the study
* Treatment with any investigational drug within 30 days prior to registration
* Patients should not have current regimen containing dietary phytonutrients